{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fourth+R",
    "query": {
      "intervention": "Fourth R"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fourth+R&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T00:42:52.941Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05668962",
      "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Thyroid Carcinoma",
        "Metastatic Thyroid Cancer",
        "Follicular Thyroid Cancer",
        "Unresectable Thyroid Gland Carcinoma",
        "Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Sodium Iodine I-131",
          "type": "DRUG"
        },
        {
          "name": "rhTSH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-03-01",
      "completion_date": "2026-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05668962"
    },
    {
      "nct_id": "NCT07342478",
      "title": "ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CLL / SLL",
        "CLL (Chronic Lymphocytic Leukemia)",
        "CLL, Refractory",
        "CLL, Relapsed",
        "SLL (Small Lymphocytic Lymphoma)",
        "SLL",
        "CLL",
        "CLL Progression"
      ],
      "interventions": [
        {
          "name": "Rocbrutinib",
          "type": "DRUG"
        },
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newave Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2026-04-23",
      "completion_date": "2030-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 6,
      "location_summary": "Skokie, Illinois • Bethesda, Maryland • Las Vegas, Nevada + 3 more",
      "locations": [
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07342478"
    },
    {
      "nct_id": "NCT00289783",
      "title": "Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Haemophilus Influenzae Type b",
        "Neisseria Meningitidis"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PedvaxHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "6 Weeks to 15 Months"
      },
      "enrollment_count": 4441,
      "start_date": "2006-02-22",
      "completion_date": "2008-02-26",
      "has_results": true,
      "last_update_posted_date": "2018-08-24",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 88,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00289783"
    },
    {
      "nct_id": "NCT05585918",
      "title": "The R-CITY Project: A Collaborative Intervention With Teachers and Youth",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Violence"
      ],
      "interventions": [
        {
          "name": "Second Step + R-CITY",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Second Step Only",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2021-09-15",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 1,
      "location_summary": "Towson, Maryland",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585918"
    },
    {
      "nct_id": "NCT02909673",
      "title": "School Based Program to Prevent Teen Dating Violence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Violence"
      ],
      "interventions": [
        {
          "name": "Fourth R",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "11 Years to 15 Years"
      },
      "enrollment_count": 3028,
      "start_date": "2018-01-18",
      "completion_date": "2023-12-07",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Sugar Land, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02909673"
    },
    {
      "nct_id": "NCT00394524",
      "title": "Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes or With New Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Glucommander",
          "type": "DEVICE"
        },
        {
          "name": "Standard insulin infusion algorithm",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 160,
      "start_date": "2006-06",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394524"
    },
    {
      "nct_id": "NCT05256290",
      "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Cancer",
        "NSCLC",
        "Advanced Lung Carcinoma",
        "Epidermal Growth Factor Receptor C797S",
        "Epidermal Growth Factor Receptor G719X",
        "EGF-R Positive Non-Small Cell Lung Cancer",
        "EGFR-TKI Resistant Mutation"
      ],
      "interventions": [
        {
          "name": "silevertinib (BDTX-1535) monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Black Diamond Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2022-03-31",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256290"
    },
    {
      "nct_id": "NCT07460804",
      "title": "FOA on Sit to Stand in Individuals Post Chronic Stroke",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Focus of Attention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Western Carolina University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-26",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 1,
      "location_summary": "Cullowhee, North Carolina",
      "locations": [
        {
          "city": "Cullowhee",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07460804"
    },
    {
      "nct_id": "NCT03621670",
      "title": "Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline water)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1196,
      "start_date": "2018-07-27",
      "completion_date": "2024-12-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03621670"
    },
    {
      "nct_id": "NCT01080807",
      "title": "Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Excessive Sleepiness"
      ],
      "interventions": [
        {
          "name": "Armodafinil",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cephalon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 385,
      "start_date": "2010-03",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-20",
      "last_synced_at": "2026-09-08T00:42:52.941Z",
      "location_count": 63,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burlingame",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01080807"
    }
  ]
}